Lebrikizumab As Extended Therapy in Chronic Eczema
Patients with moderate-to-severe atopic dermatitis who did not initially meet response criteria for lebrikizumab at 16 weeks can still achieve improvements with continued therapy, according to a recent clinical trial analysis.